Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma

NCT01722305 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01722305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01722305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
April 8, 2013
Completion date
July 15, 2019
Enrollment
29 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and burkitt lymphoma, central nervous system lymphoma, intraocular lymphoma, primary diffuse large b-cell lymphoma of the central nervous system, recurrent adult diffuse large cell lymphoma, retinal lymphoma